Article ID Journal Published Year Pages File Type
6000761 Thrombosis Research 2015 6 Pages PDF
Abstract

•627 patients with acute PE, with/without malignancy, were followed for 1 year at least.•The malignant group had less embolic burden compared with the non-malignancy group.•In malignancy patients, the survival time was longer in LMWH group than VKA group.•The mortality in the first 6 months was lower in LMWH group than VKA group.

BackgroundAs a special group in pulmonary embolism (PE), the baseline characteristics, better therapeutic strategy and prognosis of patients with concurrent malignancy need to be investigated. Long-term low-molecular-weight heparin (LMWH) is recommended for these patients, however, whether therapeutic strategy affects long-term prognosis remains unclear.MethodsIn this prospective study, acute symptomatic PE patients confirmed by imaging examinations, with/without malignancy, were enrolled and followed. Qanadli score was used to assess the embolic burden. The clinical endpoints included symptomatic recurrent venous thromboembolism (VTE), all-cause death and clinic relevant bleeding.ResultsIn the 627 patients enrolled, 92 patients had malignancy at baseline. The median follow-up period was 36 months. The Qanadli score at baseline was lower in malignancy group than non-malignancy group (P = 0.003). 48.9% of patients with malignancy died, while 11.4% of non-malignancy group died (P < 0.001). Malignancy was a risk factor of death (HR 5.659, 95%CI 3.090-10.366, P < 0.001). In malignancy group, 56 patients used long-term LMWH and 36 patients received oral vitamin K antagonist (VKA). The median survival time was 30 months in LMWH group, significantly longer than 12.5 months in VKA group (P = 0.041). The mortality in the first 6 months was lower in LMWH group than VKA group (19.6% vs. 41.7%, P = 0.022).ConclusionsPE patients with malignancy had much higher incidence of all-cause death in spite of less embolic burden compared with patients without malignancy. Anticoagulation using long-term LMWH could prolong the survival time of PE patients with malignancy, and it was more effective than VKA.

Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Authors
, , , , , , , ,